Symptomatic hypomagnesemia induced by proton-pump inhibitors (PPIs). A known adverse event that is worth recalling

Area of Science:

• Gastroenterology and Pharmacology

Background:

• A 2016 position statement by the Sociedad Española de Patología Digestiva addressed the safety of proton pump inhibitors (PPIs).
• The statement concluded that adverse effects associated with PPIs are infrequent and typically of minor clinical significance.

Discussion:

• The safety profile of PPIs was evaluated, considering various potential adverse events.
• Magnesium deficiency was specifically investigated as one of the adverse events linked to PPI therapy.

Key Insights:

• PPIs demonstrate a favorable safety profile, with serious adverse events being rare.
• The assessment confirmed that common side effects are generally mild and manageable.

Outlook:

• Further research may continue to refine understanding of PPI safety.
• Clinical practice guidelines emphasize the judicious use of PPIs based on established safety data.